Wall Street Weekly Report Dec 9–15 - Merlintrader Trading Pub

Wall Street Weekly Report (Dec 9–15, 2025) | Merlintrader trading Blog

Economic Events: The Week Ahead

KEY CATALYST FACT Federal Reserve FOMC Meeting (Dec 17–18) – markets are currently pricing an approximate probability of a 25 bp rate cut to 3.50%–3.75%, which would be the third cut of 2025. This decision is likely to be the single most important event affecting equity valuations in the following week.

Tuesday, Dec 9

RBA Rate Decision

Australia’s Reserve Bank widely expected to hold rates at 3.60%. Focus remains on forward guidance regarding 2026 cuts while inflation stays above target.

Wednesday, Dec 10

US Jobless Claims

Initial jobless claims expected to show continued softness in the labour market. Recent data indicates monthly payroll growth slowing from around 110k in 2024 to roughly 50k in 2025.

Thursday, Dec 11

UK GDP (Q3 Final)

UK services PMI at 51.3 (revised higher), manufacturing at 50.2. Markets expect a BOE rate cut to 3.75% on Dec 18 with relatively flat Q3 GDP growth.

Friday, Dec 12

US Core Inflation (CPI)

Core inflation around 3% YoY despite tariff pressures. Estimates suggest only 40–50% of tariff costs have been passed to consumers. Markets watch how persistent price pressures remain.

Friday, Dec 12

Retail Sales Data

Holiday shopping read-out. Affluent consumers supported by the wealth effect; lower earners show more cautious spending patterns as confidence remains weak.

Ongoing

Government Data Gaps

Recent government shutdown has delayed several official economic releases. Markets are trading with incomplete information, with potential for higher volatility when data normalises.

TRADER’S PERSPECTIVE (Not Financial Advice) PERSONAL VIEW The economic backdrop broadly supports the Fed’s dovish stance, but much of the potential rate cut appears already reflected in prices. The real catalyst will be Chair Powell’s commentary and the updated path for 2026 policy. Market pricing indicates expectations of multiple additional 25 bp cuts next year. At the same time, uncertainty around future Fed personnel and Trump administration policies adds downside risk to guidance and may justify an extra risk premium. This is a personal observation based on public data, not a forecast or investment recommendation.

Trump Factor: Policy Implications for Markets

Tariffs Uncertainty: Supreme Court review may change the legal basis of IEEPA tariffs (roughly 100B USD collected in 2025), forcing a pivot toward Section 232/301 frameworks. This creates potential refund risk but could also bring more clarity on the future policy architecture. Labour-intensive small/mid caps remain under pressure, while capital-intensive firms benefit from tax incentives.

Fiscal Easing via “One Big Beautiful Bill Act”: Front-loaded tax incentives and investment credits are supporting some companies. Retroactive capex credits create one-time cash benefits for corporations and may support growth into 2026, although effects are likely concentrated among higher-margin beneficiaries.

AI Investment Acceleration: Tariff and tax policy has indirectly accelerated AI adoption and margin expansion through labour cost optimisation. Large technology platforms and AI infrastructure players benefit, while labour-intensive sectors face pressure. Real household labour income growth remains below 1%.

Immigration Policy Impact: Tighter immigration reduces labour supply. Breakeven monthly payroll growth is estimated to have fallen from around 200k (2023–24) to roughly 50k (2025). Unemployment has risen despite slower job creation, as labour demand falls faster than labour supply. Wage pressure concentrates on high-skill roles, with disinflation in many lower-skill segments.

Fed Chair Uncertainty: Public criticism of Jerome Powell introduces personnel risk around the May Fed meeting. Potential leadership change could alter the policy framework. Market participants price an additional risk premium; bond volatility remains elevated.

TRADER OBSERVATION PERSONAL VIEW Based on earnings and price data, winners and losers appear increasingly bifurcated. Large-cap tech and capital-intensive industrials show resilience, while small-cap, labour-dependent retail/construction/services look more vulnerable. Public credit-market data suggests an elevated risk of a default cycle among weaker credits over the next year, with spreads widening in fragile segments. This is an observational framework based on public information and should not be interpreted as guidance or investment advice.

Hottest Stocks: Small Caps and Biotech (Week of Dec 9–15)

MARKET BACKDROP FACT Small-cap equities outperformed in November (around +2.5%), now trading at an estimated discount to fair value relative to large caps that appear slightly rich on many metrics. The recent volatility pullback in Bitcoin and other risk assets has shaken out part of the retail euphoria; buyback programmes provide a partial floor for indices.

Ticker	Company	Theme	12-Week Move	Key Driver / Catalyst	Risk / Reward Label
VCYT	Veracyte Inc	Diagnostic Biotech	+48.8%	Oncology diagnostic pipeline; AI integration in assay development.	Moderately positive narrative \| P/E 28.7
NBIX	Neurocrine Biosciences	CNS/Psych Therapeutics	+7.4%	Projected strong EPS growth into 2026; neuro-psych pipeline expansion.	Positive narrative \| P/E 22.3
KROS	Keros Therapeutics	Rare Disease	+28.6%	High EPS growth projections; focused rare-disease portfolio.	Very constructive \| P/E 9.0
ARQT	Arcutis Biotherapeutics	Dermatology Biotech	+76.1%	Pipeline momentum; strong revenue-growth expectations; no near-term dated catalysts.	High-beta positive \| P/E n/a
FOLD	Amicus Therapeutics	Lysosomal Storage	+24.1%	EPS growth, rare-disease tailwinds, expanding international footprint.	Positive \| P/E 28.0
BMRN	BioMarin Pharmaceutical	Rare Genetic Disease	Consolidation	Six marketed therapies; strong PKU franchise; solid FCF profile.	Quality bias \| valuation seen as reasonable
EXEL	Exelixis Inc	Oncology	Approx. +33% since Oct	Cabometyx growth, new combo data, margin expansion.	Strong positive narrative \| valuation not extreme
REGN	Regeneron Pharmaceuticals	Large-Cap Biotech	Stable	AI-driven discovery, GLP-1 partnerships, ophthalmology pipeline.	Defensive quality profile
TYRA	Tyra Biosciences	Precision Oncology	Momentum	Targeted cancer therapeutics; AI-assisted patient stratification.	High growth, speculative
GHRS	GH Research Ltd	Psychedelic Medicine	Emerging	Novel approach to depression/PTSD; regulatory pathway gradually clearer.	High risk / high potential payoff

BIOTECH SECTOR OBSERVATION PERSONAL VIEW Based on public valuation metrics and sector flows, small-cap biotech currently appears to trade at a discount versus larger peers. AI-driven narratives around drug discovery shorten perceived timelines, while a dense FDA pipeline provides multiple potential catalysts. At the same time, the sector is exposed to rotation risk if the December Fed outcome or macro data disappoint. This is an interpretative view built on public data and should not be read as a sector recommendation or an invitation to trade.

Sentiment – Top 10 Trending Stocks on Social Media (X, Stocktwits, Reddit)

METHODOLOGY FACT Sentiment is derived from retail trading communities (Stocktwits trending ranks, X financial hashtags, Reddit r/stocks and r/wallstreetbets). Labels such as “bullish” or “bearish” reflect aggregated comments and emoji usage in those communities and do not represent professional research or institutional positioning.

RDDT

Reddit Inc

Extremely bullish retail tone

Approx. +97% YTD

Strong quarter with AI-driven ad narrative. Retail communities highlight it as a leading momentum name.

BMRN

BioMarin Pharma

Bullish

High volume

Free-cash-flow and rare-disease moat discussed as long-term positives; perceived institutional accumulation.

EXEL

Exelixis

Very bullish

Approx. +33% recent

Oncology-driven margin expansion, strengthening narrative around key assets.

Extended Sentiment Deep Dive: Trend Patterns and Momentum Labels

Extreme Positive Bias (Accumulation-type Behaviour)

Example tickers: RDDT, EXEL, VCYT, ARQT
Signals discussed: daily volume spikes versus 20-day averages, strong skew in bullish comments, and call/put activity biased to the upside. Historically, such phases can precede sharp pullbacks once larger players start to lock in profits.

Positive Trend (Consolidation and Breakout Potential)

Example tickers: META, BMRN, PINS, ASND, NBIX
Signals discussed: steady accumulation, improving comment tone week-over-week and narratives supported by fundamentals (AI, free-cash-flow, pipeline). Traders often frame these as candidates for further upside, but this remains their personal view.

Neutral / Mixed (Indecision and Range Trading)

Example tickers: SNAP, YELP, RKLB
Signals discussed: conflicting narratives, sentiment swinging quickly, prices hovering near technical levels where either breakout or breakdown is possible. Some traders mention option strategies such as straddles or strangles in this context; this is a description of what they do, not a suggestion to use those strategies.

Cooling or Negative Bias (Profit-Taking Phase)

Example tickers: NVDA
Signals discussed: sentiment indicators retreating from prior extremes, more frequent mentions of valuation risk and competition, and an increase in protective positioning. Historically this has sometimes preceded consolidation phases rather than a full trend reversal, but outcomes vary.

Strongly Negative Bias (Capitulation Risk)

Example tickers cited by traders: TSLA (deteriorating tone), LUMN (structural-decline narratives)
Signals discussed: majority of comments negative, volume spikes on down days, frequent references to “avoid until fundamentals stabilise”. Again, this is a retail narrative snapshot, not a fundamental credit or equity opinion.

Special Situations (Binary Event Setups)

Example tickers: INVA (Zoliflodacin FDA decision), MSTR (Bitcoin-linked exposure)
Signals discussed: event-driven positioning where sentiment is dominated by expectations about a single catalyst (regulatory or macro). Outcomes are typically modelled by traders as wide ranges (large potential gains or losses) and are highly sensitive to the actual event.

Sentiment Momentum Tracking – Weekly Shift:

Comparing late November to early December, discussions show stronger positive bias around RDDT, EXEL, BMRN and VCYT, modest loss of momentum around SNAP/YELP, and weaker enthusiasm around some mega caps such as NVDA and TSLA. These are simply aggregated impressions from public comment streams and should always be cross-checked with fundamentals, official filings and personal risk tolerance.

Earnings Calendar: Selected Reports (Week of Dec 9–15)

EARNINGS CONTEXT FACT The Q3 2025 earnings season is winding down. December reports are important mainly for how companies update full-year 2026 guidance in light of Trump tariffs, immigration effects, and the Fed’s rate path. Markets are alert to margin compression warnings in labour-intensive sectors.

Date	Company / Ticker	Sector	Est. EPS	Key Watch Items	Sentiment Label
Dec 9 AM	DELL	Enterprise Tech / Hardware	$0.94	AI server demand, gross-margin trajectory, 2026 guidance on enterprise spending.	Constructive
Dec 10 AM	CRWD	Cybersecurity / SaaS	$0.72	ARR growth, net-retention metrics, consolidation of security spend.	Constructive
Dec 10 PM	LUMN	Telecom Infrastructure	-$0.08	Legacy decline, asset-monetisation progress, ability to pass tariff costs through.	Cautious
Dec 11 AM	SMCI	AI Infrastructure / Hardware	$0.61	Server shipments, GPU demand durability, supply-chain normalisation.	Positive momentum
Dec 11 PM	TSLA	EV / Automotive	$0.66	Delivery trends, gross-margin impact of pricing, progress on new products, tariff sensitivities.	Cautious
Dec 12 AM	ADBE	Software / Creative Cloud	$3.18	Adoption of AI features, pricing power, enterprise stabilisation post regulatory concerns.	Constructive
Dec 12 PM	UBER	Gig Economy / Mobility	$0.43	Unit-economics in delivery, profitability trajectory, wage-inflation pass-through.	Constructive
Dec 13 AM	RKLB	Space / Launch	$-0.09	Competitive pricing, contract pipeline and government-spending visibility.	Mixed
Dec 13 PM	MSTR	Bitcoin-Linked Exposure	N/A	Bitcoin holdings mark-to-market, regulatory commentary, treasury strategy.	Highly volatile
Dec 15 AM	HRI	Biotech / Small Cap	$-0.15	Trial progress, cash-burn profile, clarity on pipeline milestones.	Speculative

EARNINGS SEASON OBSERVATION PERSONAL VIEW From public estimates and guidance, AI-related infrastructure and software names show strong growth expectations but may face margin pressure from competition and component costs. In contrast, segments like legacy telecom and parts of the EV space are more exposed to guidance cuts. Comments here are meant as an analytical framework and not as earnings trades or recommendations.

FDA Catalysts: Key Approval Decisions (Week of Dec 9–15)

KEY CONTEXT FACT December 2025 includes numerous scheduled FDA decisions. The week of Dec 9–15 concentrates several approvals and resubmissions that could materially move related biotech equities. Priority reviews and orphan-drug designations can affect expectations but do not guarantee outcomes.

December 11, 2025

BLUJEPA (Gepotidacin) – sBLA

Company: GSK plc

Indication: Expanded use for uncomplicated urogenital gonorrhoea in patients aged 12+.
Significance: Antibiotic-resistance trends create potential pricing power for novel agents. GSK builds out its gonorrhoea franchise with a first-in-class agent in this category.

December 12, 2025

ORLADEYO (berotralstat) – NDA

Company: BioCryst Pharmaceuticals (BCRX)

Indication: Hereditary angioedema (HAE) prophylaxis in paediatric patients aged 2–11 years.
Significance: Ultra-rare orphan disease with limited options. Paediatric expansion could open additional market share but market reaction will depend on label details and commercial execution.

December 13, 2025

CARDAMYST (ivabradine) – Resubmitted NDA

Company: Milestone Pharmaceuticals

Indication: Paroxysmal supraventricular tachycardia (PSVT).
Significance: Resubmission following a prior Complete Response Letter. PSVT remains an under-served subset within arrhythmia care. Approval would validate the formulation and strategy; rejection would highlight the risk of relying on single-asset stories.

December 14, 2025

UPLIZNA (inebilizumab) – sBLA

Company: Amgen

Indication: Generalised myasthenia gravis (gMG).
Significance: Expansion of Amgen’s immunology portfolio into gMG; large-pharma infrastructure could support rapid uptake if approved.

December 15, 2025

ZOLIFLODACIN – NDA

Company: Innoviva (INVA)

Indication: Uncomplicated gonorrhoea in adults and patients aged 12+.
Significance: Major event: first-in-class spiropyrimidinetrione oral antibiotic with Priority Review and QIDP designation. Given the antibiotic-resistance backdrop, this decision could be important both medically and for Innoviva’s profile. Market reactions are highly dependent on the exact label and any safety language in the approval or rejection.

FDA DECISIONS OBSERVATION PERSONAL VIEW This week’s FDA calendar leans heavily toward infectious disease, orphan-disease expansions and arrhythmia management. The Zoliflodacin decision for INVA stands out as a focal point for traders following infectious-disease pipelines. Historically, biotech indices can show 2–5% swings around clusters of high-profile approvals or setbacks, but each case is path-dependent. Nothing in this section should be read as a probability estimate or as a trade idea.

Important Legal and Risk Disclaimer – USA, EU and Italy

Purpose of this report: This document is for informational and educational purposes only. It does not constitute investment advice, a recommendation, an offer, or a solicitation to buy or sell any financial instrument. All views expressed are personal market observations based on public data as of December 6, 2025. Markets can change rapidly; the information may become outdated or incomplete.

Regulatory perspective (USA – SEC/FINRA): The author is not a registered investment adviser, broker-dealer, or research analyst. Any forward-looking statements are inherently uncertain and involve risks as described in companies’ official SEC filings (10-K, 10-Q, 8-K, S-1 and similar). This report is intended to be consistent with general anti-fraud and fair-disclosure principles but it is not a regulated research product. Readers should always refer to original SEC filings and official company communications for primary information.

EU / ESMA / MiFID II and CONSOB considerations: For readers in the European Union and in Italy, this document is classified as personal market commentary from a private trader and not as “investment research” or “investment advice” under MiFID II. It does not take into account your objectives, financial situation or risk profile. In Italy, any investment decision should be discussed with a financial advisor or intermediary authorised and supervised by CONSOB. This report is not a substitute for the suitability and appropriateness checks required by European regulation.

Conflicts of interest and holdings: The author may hold, or have held, positions (long or short) in some of the securities mentioned. No guarantee is given that any position will be disclosed in real time or kept up to date. Nothing in this report should be interpreted as a signal to mirror any position or strategy. Always make independent decisions.

Data quality and sources: Market data and examples are derived from public sources such as SEC filings, company press releases, official FDA calendars, central-bank communications, and reputable news outlets (for example Bloomberg, Reuters, major financial media) together with sentiment data from retail communities (Reddit, Stocktwits, X). While care is taken to cross-check information, errors or omissions are possible. If you notice a factual error, you are invited to report it so it can be corrected.

High-risk segments warning: Biotech, small caps, event-driven trades and derivative strategies can involve very high volatility, rapid gaps and total loss of capital. Binary FDA events, earnings surprises and macro shocks can result in intraday moves of 30–50% or more. These dynamics are described here only as examples; they are not an invitation to participate in such trades.

Avvertenza Importante su Rischi e Regolamentazione – USA, UE e Italia

Finalità del rapporto: Questo documento ha finalità esclusivamente informative e didattiche. Non costituisce consulenza in materia di investimenti, raccomandazione, offerta o sollecitazione all’acquisto o alla vendita di strumenti finanziari. Le opinioni espresse sono osservazioni personali di mercato, basate su dati pubblici disponibili al 6 dicembre 2025. I mercati possono cambiare rapidamente; le informazioni possono diventare rapidamente superate o incomplete.

Prospettiva regolamentare (USA – SEC/FINRA): L’autore non è un consulente finanziario registrato, né un analista o intermediario abilitato. Eventuali affermazioni di tipo prospettico sono intrinsecamente incerte e comportano rischi come descritto nei documenti ufficiali depositati presso la SEC (10-K, 10-Q, 8-K, S-1 e simili). Questo rapporto è inteso per essere coerente con i principi generali di trasparenza e correttezza informativa, ma non è ricerca regolamentata. Per le informazioni primarie occorre sempre fare riferimento ai documenti ufficiali delle società.

MiFID II, ESMA e CONSOB (Italia/Europa): Per i lettori europei e in particolare italiani, questo documento va inteso come commento personale di mercato da parte di un trader privato e non come “ricerca in materia di investimenti” o “consulenza in materia di investimenti” ai sensi della MiFID II. Non tiene conto degli obiettivi, della situazione finanziaria, né del profilo di rischio del singolo lettore. In Italia, ogni decisione di investimento dovrebbe essere discussa con un consulente finanziario o intermediario autorizzato e vigilato da CONSOB. Questo rapporto non sostituisce i questionari di adeguatezza e appropriatezza previsti dalla normativa.

Conflitti di interesse e posizioni personali: L’autore può detenere, o avere detenuto, posizioni (lunghe o corte) su alcuni dei titoli citati. Non vi è alcuna garanzia che tali posizioni vengano comunicate in tempo reale o mantenute aggiornate. Nulla di quanto scritto deve essere interpretato come invito a replicare posizioni o strategie.

Qualità dei dati e fonti: I dati di mercato e gli esempi riportati derivano da fonti pubbliche quali documenti SEC, comunicati stampa ufficiali delle società, calendari FDA, comunicazioni delle banche centrali e testate finanziarie primarie (ad esempio Bloomberg, Reuters, principali media finanziari), oltre a dati di sentiment provenienti da community retail (Reddit, Stocktwits, X). Pur cercando di verificare le informazioni, errori e omissioni sono possibili. Se rilevi un errore fattuale, ogni segnalazione è benvenuta per poterlo correggere.

Avvertenza su segmenti ad alto rischio: Biotech, small cap, strategie event-driven e strumenti derivati possono comportare volatilità molto elevata, gap improvvisi e perdita totale del capitale investito. Gli eventi binari (FDA, earnings, shock macro) possono generare movimenti intraday del 30–50% o più. Questi aspetti sono descritti qui solo a titolo di esempio e non come invito a partecipare a operazioni di questo tipo.

Tools, Research Partners and Support

The tools below are those I personally use to read the market: screeners, research platforms, charting and sentiment dashboards. Links may include referral or affiliate tracking; using them costs you nothing extra and helps keep Merlintrader trading Blog free for readers.

Strumenti, Partner di Ricerca e Supporto

Gli strumenti indicati sono quelli che utilizzo personalmente per seguire il mercato: screener, piattaforme di ricerca, grafici e dashboard di sentiment. I link possono includere parametri di referral o affiliazione; usarli non ha costi aggiuntivi per te e aiuta a mantenere Merlintrader trading Blog gratuito per chi legge.

Finviz – Screener and Heatmaps

High-level market view, sector heatmaps and stock screeners, including many of the tickers mentioned in this report.

Open Finviz

Seeking Alpha – Deep Fundamental Research

Fundamental and earnings-driven deep dives, transcripts and quant ratings, useful as a complement to this type of weekly overview.

Explore Seeking Alpha

Stocktwits – Retail Sentiment Stream

Real-time stream of trader comments and sentiment labels for many of the most mentioned stocks in this report.

Open Stocktwits

Medved Trader – Active Trading Platform

Advanced charting, tape reading and order-routing platform used for intraday management of many of the strategies discussed on Merlintrader trading Blog.

Visit Medved Trader

If you find value in this kind of work and would like to help keep the site independent and free for everyone:

Se trovi utile questo tipo di lavoro e vuoi aiutare a mantenere il sito indipendente e gratuito per tutti:

Donate via PayPal

Author’s note (EN)

In every report I share things as I personally interpret them, based on raw data from official filings, company communications and primary verified sources where available. I do not write to promote enthusiasm or pessimism; these are simply my own views as a trader like you, not as a professional analyst. Market sentiment can shift quickly. Official documents and numbers remain what they are.

It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Remember that I am not a professional; do not expect perfection here, only transparency, data and consistent effort.

Nota dell’autore (IT)

In ogni report condivido ciò che vedo e come lo interpreto personalmente, partendo da dati grezzi provenienti da documenti ufficiali, comunicazioni societarie e fonti primarie verificate quando disponibili. Non scrivo per creare entusiasmo o pessimismo; sono semplicemente le mie opinioni da trader come te, non da analista professionista. Il sentiment di mercato può cambiare molto rapidamente; i documenti ufficiali e i numeri rimangono quelli che sono.

È anche possibile che commetta errori: raccogliere e incrociare cronologie FDA, dati clinici, filing e aggiornamenti societari è un lavoro complesso, quindi qualche imprecisione può sfuggire. Se noti qualcosa che non ti torna, segnalamelo e farò il possibile per correggerlo. Ricorda che non sono un professionista: non aspettarti perfezione, ma trasparenza, dati e impegno costante.

Authors: Merlintrader and Jane.

Wall Street Weekly Report – Personal Market Observations Rapporto Settimanale di Wall Street – Osservazioni Personali di Mercato

Week of December 9–15, 2025 | Educational content only – not investment advice. Settimana 9–15 dicembre 2025 | Contenuto didattico – non è consulenza di investimento.

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Authors: Merlintrader, Jane and Gemini

Author's note (English)

In every report I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this report as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

AI usage disclosure (English)

This report has been prepared using a human + AI workflow. Drafting, editing and data organisation are supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Legal disclaimer (English) – please read carefully

This report is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in this document should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in this report, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this document is not investment advice and should not be used as such.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana che inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicated here sotto.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Tools and research platforms used in this report

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Some of the links above are affiliate links. If you decide to subscribe or purchase through them, it may generate a small commission for Merlintrader at no extra cost to you. This helps keep the site online and the reports freely accessible. You are under no obligation to use these links; always choose the solution that best fits your needs and your own evaluation.

Full legal information, risk warnings and terms of use (in both Italian and English) are available on the official Merlintrader legal pages:

Italian version: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Authors: Merlintrader, Jane and Gemini

Nota dell'autore (Italiano)

In ogni report condivido ciò che vedo e come lo interpreto personalmente, partendo dai dati grezzi di documenti ufficiali, comunicazioni delle società, trascrizioni delle call e altre fonti primarie quando disponibili. Alcune parti del lavoro di ricerca e di impaginazione sono supportate da assistenti IA (Jane e Gemini), che mi aiutano a organizzare i dati, verificare i dettagli e migliorare grafici o elementi visivi. Le valutazioni finali, le opinioni e le conclusioni restano comunque esclusivamente mie, da trader come te, non da consulente finanziario abilitato o analista iscritto ad albi professionali. Il sentiment di mercato può cambiare molto rapidamente, mentre i documenti ufficiali e i numeri restano quelli che sono. È anche possibile che commetta errori: raccogliere e confrontare tempistiche FDA, dati clinici, filing e aggiornamenti societari è un lavoro complesso, quindi qualche imprecisione può sfuggire. Se noti qualcosa che non ti torna, segnalamelo e lo correggerò. Non considerare questo report come consulenza personalizzata, ma come materiale informativo da confrontare con le tue ricerche e con il parere di professionisti qualificati.

Informativa sull'uso di IA generativa (Italiano)

Questo report è stato redatto utilizzando un flusso di lavoro combinato umano + IA. La stesura, la revisione e l'organizzazione dei dati sono supportate da strumenti di intelligenza artificiale generativa, ad esempio modelli linguistici di grandi dimensioni forniti da terze parti, sulla base di istruzioni e controlli definiti dall'autore. Le fonti utilizzate sono pubbliche e la selezione finale delle informazioni, le verifiche, le opinioni e le conclusioni restano sotto la responsabilità esclusiva dell'autore.

Disclaimer legale (Italiano) – leggere con attenzione

Questo report ha finalità esclusivamente informative e didattiche. Non costituisce in alcun modo consulenza in materia di investimenti, ricerca in materia di investimenti in senso regolamentare, gestione di portafogli, né raccomandazione personalizzata o generica ad acquistare, vendere o detenere strumenti finanziari. L'autore non è un consulente finanziario abilitato all'esercizio della professione, non è un promotore finanziario, non è un analista iscritto ad albi professionali e non svolge servizi di investimento ai sensi della normativa vigente.

Qualsiasi riferimento a scenari possibili, livelli di prezzo, probabilità o catalyst ha valore puramente illustrativo e riflette una valutazione personale e non professionale basata su informazioni pubbliche disponibili al momento della stesura. Nulla di quanto scritto rappresenta sollecitazione al pubblico risparmio, offerta al pubblico di prodotti finanziari o promessa di rendimento o di protezione del capitale. In particolare, i titoli biotech e healthcare possono essere estremamente volatili e speculativi, soprattutto in prossimità di eventi clinici o regolatori (PDUFA, letture di trial, ecc.).

L'autore può detenere, o aver detenuto, posizioni long o short su alcuni degli strumenti finanziari menzionati nel report e può aprire, chiudere o modificare tali posizioni senza preavviso. Questa possibile coincidenza di interessi può influenzare il taglio o l'attenzione dell'analisi. La presenza di eventuali posizioni personali non trasforma in alcun modo questo documento in consulenza finanziaria e non deve essere interpretata come tale.

Prima di assumere qualsiasi decisione di investimento o di trading, è indispensabile effettuare le proprie analisi e valutazioni e, se necessario, rivolgersi a un consulente finanziario indipendente e abilitato, in grado di considerare la tua situazione personale, gli obiettivi e la propensione al rischio. Le informazioni riportate possono contenere errori, omissioni o non essere aggiornate; né l'autore né Merlintrader possono essere ritenuti responsabili per eventuali perdite, dirette o indirette, derivanti dall'utilizzo di questo contenuto.

I testi completi dei disclaimer e delle condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali del sito Merlintrader, indicate qui sotto.

Se trovi utili questi report e vuoi sostenere il progetto, puoi fare una donazione volontaria una tantum tramite PayPal o Buy Me a Coffee. È un aiuto concreto per coprire i costi di dati, strumenti e hosting, così i contenuti possono restare indipendenti e liberamente accessibili.

Strumenti e piattaforme di ricerca usati in questo report

Qui sotto trovi una selezione di strumenti e piattaforme che uso personalmente per seguire prezzi, catalyst, fondamentali e sentiment. I link sono forniti solo per trasparenza e comodità del lettore.

Finviz Elite – screener avanzato e piattaforma grafica, usato per heatmap, performance relative e contesto tecnico.
ChartsWatcher – scanner real-time di nuova generazione per il mercato azionario USA. Lo uso per monitorare momentum intraday, picchi di volume e alert cromatici sui pattern.
Stocktwits – flusso social focalizzato sui ticker, usato solo come indicatore di sentiment e attività, non come fonte di raccomandazioni di investimento.
Monica.im – assistente AI usato per report leggeri, drafting e ricerche veloci; utile per strutturare note e prime analisi insieme al lavoro di approfondimento pubblicato su Merlintrader.
Medved Trader – piattaforma professionale di trading e charting usata per esecuzione real-time, order-flow e analisi intraday dettagliata. Nessun affiliate link; è citata perché fa parte del workflow operativo reale.
Merlintrader trading Blog – la casa dei report focalizzati sul biotech, delle dashboard e degli articoli educativi che approfondiscono i temi menzionati in questo documento.

Alcuni dei link sopra indicati sono link affiliati. Se decidi di iscriverti o acquistare tramite uno di essi, Merlintrader potrebbe ricevere una piccola commissione senza costi aggiuntivi per te. Questo aiuta a mantenere il sito online e i report liberamente accessibili. Non hai alcun obbligo di usare questi link: scegli sempre la soluzione che ritieni più adatta alle tue esigenze e alla tua valutazione personale.

Le informazioni legali complete, le avvertenze sui rischi e le condizioni d'uso, in versione sia italiana sia inglese, sono disponibili nelle pagine legali ufficiali di Merlintrader:

Versione italiana: Disclaimer e avvertenze sui rischi | Condizioni d'uso e informativa sulla privacy

Le stesse pagine includono anche il testo corrispondente in inglese o un equivalente inglese delle principali avvertenze legali, così anche i lettori internazionali possono consultare le informazioni essenziali su rischi e condizioni d'uso.

Biotech Catalyst Calendar

Per una visione più ampia e continuamente aggiornata dei prossimi catalyst biotech (date PDUFA, principali letture cliniche, eventi regolatori e conferenze chiave), puoi consultare il calendario dedicato su Merlintrader.

Apri il Biotech Catalyst Calendar